# 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

> **NCT04663997** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 200 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04663997
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-11
- **Primary completion:** 2025-08-25
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663997, "177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04663997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*